UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
May 10, 2004
---------------------------
(Date of Report)
ELITE PHARMACEUTICALS, INC.
-----------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-45241 22-3542636
------------ ------------- --------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
165 Ludlow Avenue, Northvale, New Jersey 07647
---------------------------------------------------------------
(Address of principal executive offices)
(201) 750-2646
---------------------
(Registrant's telephone number, including area code)
Item 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
The Registrant issued on May 10, 2004, a press release announcing an
agreement between its wholly owned subsidiary, Elite Laboratories Inc., and
Purdue Pharma L.P. ("Purdue"), granting Purdue the exclusive right to evaluate
certain of Registrant's abuse resistance drug formulation technology and an
exclusive option to negotiate a license to develop and commercialize oxycodone
products under the technology.
A copy of Registrant's press release is attached as Exhibit 99.1.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
a) Not applicable.
b) Not applicable.
c) Exhibits
99.1. Press Release, dated May 10, 2004
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: May 10, 2004
ELITE PHARMACEUTICALS, INC.
By: /s/ BERNARD BERK
------------------------------
Name: Bernard Berk
Title: Chief Executive Officer